Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter
Rhea-AI Summary
Ping An Biomedical (Nasdaq: PASW) received a Nasdaq Minimum Bid Price Deficiency Letter after its closing bid price failed to meet the $1.00 minimum for the period Oct 10, 2025–Nov 20, 2025. Nasdaq provided an 180-calendar-day compliance period ending May 25, 2026 to regain compliance.
If not cured, the company may be eligible for an additional 180 days only if it meets market value and other initial listing standards (except bid price) and files intent to cure; otherwise Nasdaq may issue a delisting notice. The company is evaluating options, including a possible reverse stock split, but cannot assure successful compliance.
Positive
- Nasdaq granted a 180-day compliance period until May 25, 2026
- Potential additional 180-day cure window if other listing standards met
Negative
- Closing bid price below $1.00 for Oct 10–Nov 20, 2025
- Risk of Nasdaq delisting if deficiency is not cured
- Possible reverse stock split may be required to regain compliance
- No assurance company will regain compliance within the period
Insights
Nasdaq notified Ping An Biomedical of a minimum bid price deficiency; compliance required by
Business mechanism: Nasdaq found the company failed the minimum $1 bid price test for the period from
Dependencies and risks: Regaining compliance depends solely on restoring the closing bid price above
Concrete items to watch within the next six months: the closing bid price trajectory through
Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter.
On November 24, 2025, Ping An Biomedical Co., Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from October 10, 2025 to November 20, 2025, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of
Nasdaq has provided the Company with an 180 calendar days compliance period, or until May 25, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.
The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
ABOUT PING AN BIOMEDICAL CO., LTD.
Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the trading of its Ordinary Shares or the closing of the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contacts
Ping An Biomedical Co., Ltd. Investor Relations Contact:
Building 13, No. 1 Headquarters, No. 5 Kechuang 2nd Street, Tongzhou District, Beijing
Tel : +8618910841158
Email: liupijun2025@163.com
FAQ
What did Ping An Biomedical (PASW) receive from Nasdaq on Nov 24, 2025?
How long does PASW have to regain Nasdaq compliance?
Can PASW get more time to cure the Nasdaq deficiency?
What actions might PASW take to regain Nasdaq compliance?
What happens if PASW does not regain compliance by May 25, 2026?
